Table 4.
Secondary Prevention goals during the follow-up period for MACE subgroups.
| Secondary Prevention Profiles at the time of MACE | Total MACE population | G1 MACE (N = 147) | G2 MACE (N = 26) | P Value |
|---|---|---|---|---|
| Statin Usage | 147 (84 %) | 122 (83 %) | 22 (84 %) | 0.838 |
| Mean Dose of Daily Atorvastatin (mg/dl) | 40 (IQR = 20–40) | 40 (IQR = 20–40) | 40 (IQR = 20–40) | 0.334 |
| LDL (mg/dl) | 79 (IQR = 61–101) | 77 (IQR = 60–97) | 84 (IQR = 76–107) | 0.125 |
| DAPT usage | 148 (85.5 %) | 123 (84.7 %) | 22 (84 %) | 0.904 |
| Aspirin usage | 148 (85.5 %) | 125 (85 %) | 23 (88 %) | 0.647 |
∗DAPT: dual antiplatelet treatment, G1: no oncologic group, G2: Oncologic group Secondary Outcomes.